CAJ | 학술논문

目的评价甘氨双唑钠(sodium glycididazole,CMNa)在恶性肿瘤的放射增敏作用及安全性.方法对符合CMNa Ⅳ期临床研究的80例诊断明确的实体瘤患者采用三维适形放疗(three dimensional conformal radiotherapy,3D-CRT)或常规放疗,2 Gy/次,5次/周,中位照射剂量60 Gy,同期应用CMNa 800 mg/m2,每周3次;观察肿瘤近期疗效和毒性作用.结果官颈癌的近期疗效最好,有效率91.7%,其后依次是鼻咽癌85.7%、食管癌66.7%、肺癌54.5%、肝胆癌40%,全部有效率(CR+PR)62.6%,疾病控制率(CR+PR+sD)达到100%;黏膜、皮肤的不良反应最常见,但多为1～2级轻度反应,分别为51.3%和46.3%;血液毒性白细胞下降最明显,但与治疗前相比差异无统计学意义(x2=3.329,P=0.061),对肝肾功能、心电图变化均无明显影响.结论放疗结合CMNa治疗恶性肿瘤有满意的近期疗效,无明显毒性反应.
목적 평개감안쌍서납(sodium glycididazole,CMNa)재악성종류적방사증민작용급안전성.방법 대부합CMNa Ⅳ기림상연구적80례진단명학적실체류환자채용삼유괄형방료(three dimensional conformal radiotherapy,3D-CRT)혹상규방료,2 Gy/차,5차/주,중위조사제량60 Gy,동기응용CMNa 800 mg/m2,매주3차;관찰종류근기료효화독성작용.결과 관경암적근기료효최호,유효솔91.7%,기후의차시비인암85.7%、식관암66.7%、폐암54.5%、간담암40%,전부유효솔(CR+PR)62.6%,질병공제솔(CR+PR+sD)체도100%;점막、피부적불량반응최상견,단다위1～2급경도반응,분별위51.3%화46.3%;혈액독성백세포하강최명현,단여치료전상비차이무통계학의의(x2=3.329,P=0.061),대간신공능、심전도변화균무명현영향.결론 방료결합CMNa치료악성종류유만의적근기료효,무명현독성반응.
Objective To evaluate the effects and safety of CMNa on radiosensitivity enhacement for malignant tumors.Methods According to the standard protocol of CMNa Ⅳ stage clinic trial.80 patients with malignant tumors were treated with 3DCRT or conventional radiotherapy,2 Gy/fraction and five fractions weekly. Concomitance CMNa were applied in intravenous 800 mg/m2,three times weekly.The treatment effects and side- effects were observed.Results The curative effeet rates were 91.7%for cervical cancer.85.7% fornasopharynx cancer,56.7%for esophageal cancer,54.5%for lung cancer.40%for liver and gall cancer.The total curative effect rate was 62.6%and the tumor eontrol rate was 100%.The side-effects occulrence rates of mucosa and skin which were grades 1 to 2,were 51.3%and 46.3%,respectively,which were the highest in all side-effects.There were no statistical significances between before and after treatment on the side-effects and blood test.Conclusions CMNa combined with radiotherapy call enhance the control rates of tumors with low toxicity and high safety.